Last reviewed · How we verify
Qizhiweitong granule
Qizhiweitong granule, developed by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, is a marketed drug with a key composition patent expiring in 2028. The drug's primary strength lies in its unique mechanism of action, which differentiates it from existing treatments. The primary risk is the lack of revenue data and key trial results, which may limit its market valuation and investor confidence.
At a glance
| Generic name | Qizhiweitong granule |
|---|---|
| Sponsor | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: